/

Empresas

Gi

No verificado

Gilead Sciences, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosSaludSanidad

131 Comunicados de prensa

Ver todos los comunicados de prensa

15/06/2026

Industria

VIH, SIDA y enfermedades autoinmunes

Salud

Higiene alimentaria

Sanidad

Medicina - Varios

Farmacéutica

Biotecnología

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Fuente

Gilead Sciences, Inc.

Editor

1.00

0

12/06/2026

Industria

Salud

VIH, SIDA y enfermedades autoinmunes

Sanidad

Farmacéutica

Biotecnología

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

Fuente

Gilead Sciences, Inc.

Editor

1.00

0

11/06/2026

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Fuente

Gilead Sciences, Inc.

Editor

1.00

0

08/06/2026

Multimedia

Industria

Ciencia

Sanidad

Farmacéutica

VIH, SIDA y enfermedades autoinmunes

Biotecnología

Medicina - Varios

Higiene alimentaria

Salud

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Fuente

Gilead Sciences, Inc.

Editor

1.00

0

05/06/2026

Biotecnología

VIH, SIDA y enfermedades autoinmunes

Sanidad

Salud

Farmacéutica

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

Fuente

Gilead Sciences, Inc.

Editor

1.00

0

04/06/2026

Multimedia

Salud

Sanidad

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Mercado laboral

Mercado de valores

Industria

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

Fuente

Gilead Sciences, Inc.

Editor

1.00

0

02/06/2026

Salud

Sanidad

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Fuente

Gilead Sciences, Inc.

Editor

1.00

0

27/05/2026

Biotecnología

Sanidad

Salud

Farmacéutica

Medicina - Varios

Eventos

Industria

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)

Fuente

Gilead Sciences, Inc.

Editor

1.00

0

22/05/2026

Industria

Biotecnología

Farmacéutica

Oncología

Salud

Higiene alimentaria

VIH, SIDA y enfermedades autoinmunes

Sanidad

Medicina - Varios

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

Fuente

Gilead Sciences, Inc.

Editor

1.00

0

22/05/2026

Industria

Oncología

Higiene alimentaria

Salud

Sanidad

Farmacéutica

Biotecnología

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

Fuente

Gilead Sciences, Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0